Advertisement

Prognostic significance of maternal urinary carbohydrate antigen 19-9 for antenatal diagnosis of posterior urethral valve associated with fetal hydronephrosis

  • Abdol-Mohammad KajbafzadehEmail author
  • Shabnam Sabetkish
  • Nastaran Sabetkish
Urology - Original Paper
  • 19 Downloads

Abstract

Purpose

To evaluate the predictive role of maternal urinary CA 19-9 as a non-invasive marker for diagnosing antenatal posterior urethral valve (PUV).

Methods

A total of 40 women in the third pregnancy trimester were enrolled. Case group (group A) consisted of 20 women with a diagnosis of antenatal PUV. Twenty women with similar gestational age, fetal sex, normal US, and no history of congenital anomalies were chosen as a control group (group B). Maternal urine samples were collected and urinary CA 19-9 was measured in both groups. The correlations between maternal urinary CA 19-9 and APD (measured during pregnancy and the initial evaluation of the newborn) were assessed. CA 19-9 level in first urine of neonates was also evaluated.

Results

The mean ± SD of maternal urine CA 19-9 was higher in PUV group compared to the control group (131.6 ± 23.8 vs. 13 ± 2.7 U/mL). In addition, there was a significant correlation between maternal urinary CA 19-9 and the APD measured at the third trimester (p < 0.001) and the initial evaluation of fetus after birth according to SFU grading system (p < 0.001). However, no significant difference was found between gestational age and urinary CA 19-9 level (p = 0.34). There was also a significant correlation between the CA 19-9 level in first urine of neonates and CA 19-9 level of maternal urine (p < 0.001).

Conclusions

This is the first time that maternal urinary CA 19-9 has been applied as a noninvasive and practical diagnostic marker in antenatal PUV.

Keywords

Prenatal diagnosis Hydronephrosis Biomarkers Urine CA 19-9 antigen 

Abbreviations

ANH

Antenatal hydronephrosis

APD

Anteroposterior renal pelvic diameter

CA 19-9

Carbohydrate antigen

SFU

Society for Fetal Urology

Notes

Funding

None of the authors has direct or indirect commercial financial incentive associating with publishing the article.

Compliance with ethical standards

Conflict of interest

None of the authors has direct or indirect commercial financial incentive associated with publishing the article and does not have any conflict of interest, and will sign the Disclosing Form.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Brown T, Mandell J, Lebowitz RL (1987) Neonatal hydronephrosis in the era of sonography. AJR Am J Roentgenol 148(5):959–963.  https://doi.org/10.2214/ajr.148.5.959 CrossRefGoogle Scholar
  2. 2.
    DeFoor W, Clark C, Jackson E, Reddy P, Minevich E, Sheldon C (2008) Risk factors for end stage renal disease in children with posterior urethral valves. J Urol 180(4 Suppl):1705–1708.  https://doi.org/10.1016/j.juro.2008.03.090 (discussion 1708) CrossRefGoogle Scholar
  3. 3.
    Sarhan O, Zaccaria I, Macher MA, Muller F, Vuillard E, Delezoide AL, Sebag G, Oury JF, Aigrain Y, El-Ghoneimi A (2008) Long-term outcome of prenatally detected posterior urethral valves: single center study of 65 cases managed by primary valve ablation. J Urol 179(1):307–312.  https://doi.org/10.1016/j.juro.2007.08.160 (discussion 312–303) CrossRefGoogle Scholar
  4. 4.
    Sidhu G, Beyene J, Rosenblum ND (2006) Outcome of isolated antenatal hydronephrosis: a systematic review and meta-analysis. Pediatr Nephrol 21(2):218–224CrossRefGoogle Scholar
  5. 5.
    Nguyen HT, Herndon CA, Cooper C, Gatti J, Kirsch A, Kokorowski P, Lee R, Perez-Brayfield M, Metcalfe P, Yerkes E (2010) The Society for Fetal Urology consensus statement on the evaluation and management of antenatal hydronephrosis. J Pediatr Urol 6(3):212–231CrossRefGoogle Scholar
  6. 6.
    Sinha A, Bagga A, Krishna A, Bajpai M, Srinivas M, Uppal R, Agarwal I (2013) Revised guidelines on management of antenatal hydronephrosis. Indian J Nephrol 23(2):83–97.  https://doi.org/10.4103/0971-4065.109403 CrossRefGoogle Scholar
  7. 7.
    Noyan A, Parmaksiz G, Dursun H, Ezer SS, Anarat R, Cengiz N (2015) Urinary NGAL, KIM-1 and L-FABP concentrations in antenatal hydronephrosis. J Pediatr Urol 11(5):249. e241–249. e246CrossRefGoogle Scholar
  8. 8.
    Suzuki K, Muraishi O, Tokue A (2002) The correlation of serum carbohydrate antigen 19-9 with benign hydronephrosis. J Urol 167(1):16–20CrossRefGoogle Scholar
  9. 9.
    Ohshio G, Ogawa K, Kudo H, Yamabe H, Higuchi K, Nakashima Y, Manabe T, Tobe T (1990) Immunohistochemical distribution of CA 19-9 in normal and tumor tissues of the kidney. Urol Int 45(1):1–3CrossRefGoogle Scholar
  10. 10.
    Kajbafzadeh AM, Keihani S, Kameli SM, Hojjat A (2017) Maternal urinary carbohydrate antigen 19-9 as a novel biomarker for evaluating fetal hydronephrosis: a pilot study. Urol 101:90–93.  https://doi.org/10.1016/j.urology.2016.10.038 CrossRefGoogle Scholar
  11. 11.
    Bhadoo D, Bajpai M, Abid A, Sukanya G, Agarwala S, Srinivas M, Deka D, Agarwal N, Agarwal R, Kumar R (2015) Study of prognostic significance of antenatal ultrasonography and renin angiotensin system activation in predicting disease severity in posterior urethral valves. J Indian Assoc Pediatr Surg 20(2):63–67.  https://doi.org/10.4103/0971-9261.151546 CrossRefGoogle Scholar
  12. 12.
    Lopez Pereira P, Martinez Urrutia MJ, Espinosa L, Jaureguizar E (2013) Long-term consequences of posterior urethral valves. J Pediatr Urol 9(5):590–596.  https://doi.org/10.1016/j.jpurol.2013.06.007 CrossRefGoogle Scholar
  13. 13.
    Simoes e Silva AC, Valerio FC, Vasconcelos MA, Miranda DM, Oliveira EA (2013) Interactions between cytokines, congenital anomalies of kidney and urinary tract and chronic kidney disease. Clin Dev Immunol 2013:597920.  https://doi.org/10.1155/2013/597920 CrossRefGoogle Scholar
  14. 14.
    Surange RS, Jeygopal NS, Chowdhury SD, Sharma NK (2001) Bedside ultrasound: a useful tool for the on-call urologist? Int Urol Nephrol 32(4):591–596CrossRefGoogle Scholar
  15. 15.
    Vemulakonda V, Wilcox D, Torok M, Hou A, Campbell J, Kempe A (2015) Inter-rater reliability of postnatal ultrasound interpretation in infants with congenital hydronephrosis. Int Urol Nephrol 47(9):1457–1461CrossRefGoogle Scholar
  16. 16.
    Assadi F, Schloemer N (2012) Simplified diagnostic algorithm for evaluation of neonates with prenatally detected hydronephrosis. Iran J Kidney Dis 6(4):284Google Scholar
  17. 17.
    Docimo SG, Silver RI (1997) Renal ultrasonography in newborns with prenatally detected hydronephrosis: why wait? J Urol 157(4):1387–1389CrossRefGoogle Scholar
  18. 18.
    González R, Schimke CM (2001) Urteropelvic junction obstruction in infants and children. Pediatr Clin N Am 48(6):1505–1518CrossRefGoogle Scholar
  19. 19.
    Rickard M, Easterbrook B, Kim S, Farrokhyar F, Stein N, Arora S, Belostotsky V, DeMaria J, Lorenzo AJ, Braga LH (2017) Six of one, half a dozen of the other: a measure of multidisciplinary inter/intra-rater reliability of the society for fetal urology and urinary tract dilation grading systems for hydronephrosis. J Pediatr Urol 13(1):80 e81–80 e85.  https://doi.org/10.1016/j.jpurol.2016.09.005 CrossRefGoogle Scholar
  20. 20.
    Aybek H, Aybek Z, Sinik Z, Demir S, Sancak B, Tuncay L (2006) Elevation of serum and urinary carbohydrate antigen 19-9 in benign hydronephrosis. Int J Urol 13(11):1380–1384CrossRefGoogle Scholar
  21. 21.
    Suzuki K (2007) Elevation of serum and urinary carbohydrate antigen 19-9 in benign hydronephrosis. Int J Urol 14(7):668–669CrossRefGoogle Scholar
  22. 22.
    Khorramirouz R, Ebadi M, Rahimi Sherbaf F, Kajbafzadeh A-M (2014) Persistent high level of urinary tumor marker carbohydrate antigen 19–9 in prenatally diagnosed dysplastic kidney. Case Rep Urol 2014:259870Google Scholar
  23. 23.
    Atar A, Oktar T, Kucukgergin C, Kalelioglu I, Seckin S, Ander H, Ziylan O, Kadioglu TC (2015) The roles of serum and urinary carbohydrate antigen 19-9 in the management of patients with antenatal hydronephrosis. J Pediatr Urol 11(3):133. e131–133. e135CrossRefGoogle Scholar
  24. 24.
    Suzuki K (2000) Renal pelvic and ureteral cancer with extremely high serum level of carbohydrate antigen 19-9 (CA 19-9): a case report. Nishi Nihon J Urol 62(12):659–663Google Scholar
  25. 25.
    Arik N, Adam B, Akpolat T, Hasil K, Tabak S (1996) Serum tumour markers in renal failure. Int Urol Nephrol 28(4):601–604CrossRefGoogle Scholar
  26. 26.
    Kajbafzadeh A-M, Elmi A, Talab SS, Emami H, Esfahani SA, Saeedi P (2010) Urinary and serum carbohydrate antigen 19-9 as a biomarker in ureteropelvic junction obstruction in children. J Urol 183(6):2353–2360CrossRefGoogle Scholar
  27. 27.
    Kutlu O, Celik O, Koksal I, Yigit S, Danisman A (2012) Serum carbohydrate antigen 19-9 levels in patients with unilateral hydronephrosis due to urinary lithiasis. Minerva Urol Nefrol 64(3):217–221Google Scholar
  28. 28.
    Muller F, Dommergues M, Mandelbrot L, Aubry M-C, Nihoul-Fekete C, Dumez Y (1993) Fetal urinary biochemistry predicts postnatal renal function in children with bilateral obstructive uropathies. Obstetr Gynecol 82(5):813–820Google Scholar
  29. 29.
    Kajbafzadeh A, Elmi A, Talab SS, Tourchi A, Abdaresfahani S (2010) Fetal urinary new biomarker for prediction of renal and pulmonary function in posterior urethral valves. J Pediatr Urol 6:S46–S47CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Pediatric Urology and Regenerative Medicine Research Center, Section of Tissue Engineering and Stem Cells Therapy, Children’s Hospital Medical CenterTehran University of Medical SciencesTehranIran

Personalised recommendations